Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
The global eradication of poliomyelitis caused by wild-type virus is likely to be completed within the next few years, despite immense logistic and political difficulties, and may ultimately be followed by the cessation of vaccination. However, the existing live-attenuated vaccines have the potential to revert to virulence, causing occasional disease, and viruses can be shed by immunocompromised individuals for prolonged periods of time. Moreover, several outbreaks of poliomyelitis have been shown to be caused by viruses derived from the Sabin vaccine strains. The appearance of such strains depends on the prevailing circumstances but poses a severe obstacle to strategies for stopping vaccination. Vaccine strains that are incapable of reversion at a measurable rate would provide a possible solution. Here, we describe the constructions of strains of type 3 poliovirus that are stabilized by the introduction of four mutations in the 5′ noncoding region compared to the present vaccine. The strains are genetically and phenotypically stable under conditions where the present vaccine loses the attenuating mutation in the 5′ noncoding region completely. Type 1 and type 2 strains in which the entire 5′ noncoding regions of Sabin 1 and Sabin 2 were replaced exactly with that of one of the type 3 strains were also constructed. The genetic stability of 5′ noncoding regions of these viruses matched that of the type 3 strains, but significant phenotypic reversion occurred, illustrating the potential limitations of a rational approach to the genetic stabilization of live RNA virus vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A long-standing disadvantage of using OPVs is that attenuated vaccine strains can revert to a neuropathogenic phenotype during their replication in the intestinal tract [9,10,11,12,13,14].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are cases of paralytic polio due to the loss of viral attenuation in the oral poliovirus vaccine (OPV), known as vaccine-derived poliovirus (VDPV).”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, domV can be modified to alter viral virulence predictably and, at the same time, increase genetic stability to the extent that reversion is at undetectable levels (Macadam et al., 2006).”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Macadam et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“These thermoresistant variants also display a significant increase in virulence (Macadam et al., 2006, Stern et al., 2017).”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Macadam et al., 2006
The cited source says what the claim attributes to it.
In the citing paper
“S15domV did not revert, consistent with published data on the genetic stability of S15 (Macadam et al., 2006), but sequences showed gradual enrichment of a product with a Leon sequence.”
From Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence (2020) · cites this paper as Macadam et al., 2006
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E., & Andino, R. (2006) · Nature · doi:10.1038/nature04388 · Cited by 1,116 · cited 1×
“It has recently been shown that a single substitution in poliovirus 3Dpol (G64S) decreased the rate of mutation threeto sixfold (42), with dramatic consequences on quasispecies diversity and tropism in vivo.”
BackgroundKew, O., Morris-Glasgow, V., Landaverde, M., Burns, C., Shaw, J., Garib, Z., André, J., Blackman, E., Freeman, C. J., Jorba, J., et al. (2002) · Science · doi:10.1126/science.1068284 · Cited by 600 · cited 1×
“The first outbreak to be reported happened during 2000 and 2001 in Hispaniola, which had been certified free of polio in 1994 along with the rest of the countries in the Americas and which had a vaccination program of declining coverage, leading to the appearance of a vaccine-derived strain which could both cause dise…”
BackgroundEvans, D. M. A., Dunn, G., Minor, P. D., Schild, G. C., Cann, A. J., Stanway, G., Almond, J. W., Currey, K., & Maizel, J. V. (1985) · Nature · doi:10.1038/314548a0 · Cited by 440 · cited 1×
“genetically unstable as the virus replicates in recipients (5, 7, 8).”
BackgroundSelf-citationStrebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A., & Hinman, A. R. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/14.2.568 · Cited by 337
Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase.
van der Werf, S., Bradley, J., Wimmer, E., Studier, F. W., & Dunn, J. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.8.2330 · Cited by 337
One hundred years of poliovirus pathogenesis
Racaniello, V. R. (2006) · Virology · doi:10.1016/j.virol.2005.09.015 · Cited by 322 · cited 1×
“Over a period of 20 years, the molecular basis of the attenuation of the Sabin strains of poliomyelitis has been studied in detail (33).”
BackgroundSkinner, M. A., Racaniello, V. R., Dunn, G., Cooper, J., Minor, P. D., & Almond, J. W. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90261-1 · Cited by 297
Self-citationCirculating vaccine-derived polioviruses: current state of knowledge.
Kew, O. M., Wright, P. F., Agol, V. I., Delpeyroux, F., Shimizu, H., Nathanson, N., & Pallansch, M. A. (2004) · PubMed · doi:10.1590/s0042-96862004000100006 · Cited by 258
Brown, B., Oberste, M. S., Maher, K., & Pallansch, M. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8973-8984.2003 · Cited by 238
Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine
Westrop, G. D., Wareham, K. A., Evans, D. M., Dunn, G., Minor, P. D., Magrath, D. I., Taffs, F., Marsden, S., Skinner, M. A., & Schild, G. C. (1989) · Journal of Virology · doi:10.1128/jvi.63.3.1338-1344.1989 · Cited by 233
Self-citation
Research works printed but not linked: 1
- World Health Organization. 1983. Requirements for poliomyelitis vaccine (oral). WHO Tech. Rep. Ser.687:107-175.
Cited by
Live attenuated vaccines: Historical successes and current challenges
Minor, P. D. (2015) · Virology · doi:10.1016/j.virol.2015.03.032 · Cited by 495
Self-citationEngineering attenuated virus vaccines by controlling replication fidelity
Vignuzzi, M., Wendt, E., & Andino, R. (2008) · Nature Medicine · doi:10.1038/nm1726 · Cited by 282
Polio vaccination: Past, present and future
Bandyopadhyay, A. S., Garon, J., Seib, K., & Orenstein, W. A. (2015) · Future Microbiology · doi:10.2217/fmb.15.19 · Cited by 276
Plotkin, S. A. (2009) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00290-09 · Cited by 256
Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence
Yeh, M. T., Bujaki, E., Dolan, P. T., Smith, M., Wahid, R., Konz, J., Weiner, A. J., Bandyopadhyay, A. S., Van Damme, P., De Coster, I., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.003 · Cited by 221
Self-citation
Metadata
- Authors
- Macadam, A. J., Ferguson, G., Stone, D. M., Meredith, J., Knowlson, S., Auda, G., Almond, J. W., & Minor, P. D.
- Affiliations
- National Institute for Biological Standards and Control (GB)
- University of Reading (GB)
- Corresponding author
- Macadam, Andrew J.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2006-09
- Volume
- 80
- Issue
- 17
- Pages
- 8653-8663
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC1563845
- OpenAlex
- W2129812184
- Cited by
- 89
- References
- 44
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 8 · 2022: 5 · 2021: 2 · 2020: 5 · 2019: 3 · 2018: 3 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 3 · 2013: 5 · 2012: 6
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Evolution and Genetic Dynamics
- Keywords
- poliovirus, live attenuated vaccine, genetic stability, 5' untranslated region, type 3 poliovirus, Sabin vaccine strains, reversion to virulence, polio eradication
- MeSH terms
- Animals, Cell Line, Chlorocebus aethiops, Drug Stability, Genotype, Humans, L Cells, Mutation, Phenotype, Poliomyelitis, Serial Passage, Serotyping, Vaccines, Attenuated, Vero Cells, Virulence, Drug Design, Poliovirus, 5' Untranslated Regions, Poliovirus Vaccines, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication. https://app.cochat.ai/papers/10.1128/jvi.00370-06
- The paper
- Macadam, A. J., Ferguson, G., Stone, D. M., Meredith, J., Knowlson, S., Auda, G., Almond, J. W., & Minor, P. D. (2006). Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication. Journal of Virology. https://doi.org/10.1128/jvi.00370-06
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.